11 Jan 2019 Governance
Leukaemia UK and Leuka have merged
We are delighted to announce that on 1 November Leuka and Leukaemia UK merged, bringing together two of the UK’s leading leukaemia and blood cancer charities to create one charity dedicated to innovative research and care for people affected by blood cancers. The two charities have joined forces under the name Leukaemia UK, uniting Leuka’s 37 years’ experience in ground-breaking medical research with Leukaemia UK’s four decades of pioneering care.
From research to care, the new charity will continue to put people affected by blood cancers at its heart. Together, Leukaemia UK aims to carry out even more world-class research and advances in care.
Leukaemia UK will be led jointly by Leuka’s CEO Olive Boles and Leukaemia UK’s CEO Angela Smith-Morgan. The charity’s new Chair of Trustees is Chris Corbin, current Chair of Leuka, who is supported by a Board including both Leuka and Leukaemia UK Trustees.
Related posts
7 November 2024
University of Southampton’s Dr Giorgia Chiodin Wins Olive Boles Innovation Award
Dr Giorgia Chiodin from the University of Southampton has been awarded the prestigious Olive Boles Innovation Award for 2024. Awarded annually to a Leukaemia UK John Goldman Fellow, this award…
29 November 2021
John Goldman Fellowship awarded to Dr Pramila Krishnamurthy
Leukaemia UK is proud to announce Dr Pramila Krishnamurthy of King’s College Hospital and King’s College London as a Leukaemia UK John Goldman Fellow co-funded by Rosetrees Trust. Dr Krishnamurthy will be using the fellowship to better understand why some leukaemia patients relapse following a stem cell transplant, and how donor lymphocyte infusion can help prevent this.
4 April 2022
Leukaemia UK launches search for five new talented Trustees
We are looking for a talented and diverse set of Trustees to join our Board, and help guide the charity as we embark on an ambitious new strategy to accelerate progress in leukaemia research to stop leukaemia devastating lives.
19 June 2023
Leukaemia UK research paves the way for personalised lymphoma treatment
Despite promising trials, standard treatment for diffuse large B-cell lymphoma (DLBCL) hasn’t changed in a decade. New treatment strategies for this type of blood cancer are urgently needed. Could the…